{"analyses":[{"ciLowerLimit":"1.13","ciPctValue":"95","ciUpperLimit":"2.58","estimateComment":"Cox proportional hazards model with treatment as the independent variable \\[placebo/sipuleucel-T\\].","groupDescription":"ITT Population - all randomized participants","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.010","paramType":"Hazard Ratio (HR)","paramValue":"1.71","statisticalMethod":"Log Rank","testedNonInferiority":false},{"ciLowerLimit":"0.388","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.884","estimateComment":"Cox proportional hazards model with treatment as the independent variable \\[sipuleucel-T/placebo\\]","groupDescription":"ITT Population - all randomized participants.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.010","paramType":"Hazard Ratio (HR)","paramValue":"0.586","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.0","upperLimit":"32.4","value":"25.9"},{"groupId":"OG001","lowerLimit":"12.3","upperLimit":"25.8","value":"21.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"Overall Survival","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects randomized to receive sipuleucel-T. Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.","id":"OG000","title":"Sipuleucel-T"},{"description":"All subjects randomized to receive placebo. Approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From randomization to 36 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}